Amin Ahmad, Maleki Majid
Department of Heart failure and Transplantation, Rajaee Cardiovascular, Medical and Research Center, Tehran University of Medical Science, Tehran, Iran.
Department of Cardiology, Rajaee Cardiovascular, Medical and Research Center, Tehran University of Medical Science, Tehran, Iran.
Heart Asia. 2012 Jan 1;4(1):16-22. doi: 10.1136/heartasia-2011-010068. eCollection 2012.
Increasing myocardial contractility has long been considered a big help for patients with systolic heart failure, conferring an augmented haemodynamic profile in terms of higher cardiac output, lower cardiac filling pressure and better organ perfusion. Though concerns have been raised over the safety issues regarding the clinical trials of different inotropes in hearts with systolic dysfunction, they still stand as a main therapeutic strategy in many centres dealing with such patients. They must be used as short in duration, low in dose and stopped as early as possible. Evidence-based guidelines have provided clinicians with valuable data for better applying inotropes in heart failure patients. In this paper, the authors address clinical trials with different agents used for increasing cardiac contractility in heart failure patients. Furthermore, the authors focus on recent guidelines on making the most out of inotropes in heart failure patients.
长期以来,增强心肌收缩力一直被认为对收缩性心力衰竭患者大有帮助,在提高心输出量、降低心脏充盈压和改善器官灌注方面可带来更好的血流动力学表现。尽管对于不同正性肌力药物用于收缩功能障碍心脏的临床试验的安全性问题存在担忧,但在许多治疗此类患者的中心,它们仍然是主要的治疗策略。必须短期、小剂量使用,并尽早停药。循证指南为临床医生在心力衰竭患者中更好地应用正性肌力药物提供了有价值的数据。在本文中,作者阐述了用于增强心力衰竭患者心肌收缩力的不同药物的临床试验。此外,作者还重点关注了关于在心力衰竭患者中充分利用正性肌力药物的最新指南。